Advanced Cholangiocarcinoma

18 clinical trials · Condition

Record	Firm	Date
IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 (NCT05805956)	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.	2022-02-15
Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma (NCT05532059)	Second Affiliated Hospital, Zhejiang University, School of Medicine	2022-01-31
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma (NCT04088188)	Academic and Community Cancer Research United	2021-01-25
Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (NCT04093362)	Taiho Oncology, Inc.	2021-01-06
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations (NCT03773302)	QED Therapeutics, a BridgeBio company	2019-12-27
Toripalimab Combined With Gemcitabine/5--fluoropyrimidine for Advanced Cholangiocarcinoma (NCT03982680)	Jiangmen Central Hospital	2019-07-13
Study of TQB2450 Combined With Anlotinib in Subjects With Advanced Cholangiocarcinoma (NCT03996408)	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	2019-06-24
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron (NCT02982720)	Aiwu Ruth He, MD	2017-07-05
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) (NCT02989857)	Institut de Recherches Internationales Servier	2017-02-20
A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma (NCT02150967)	QED Therapeutics, a BridgeBio company	2014-07-23
Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements (NCT04507503)	Taiho Oncology, Inc.

Track Advanced Cholangiocarcinoma automatically

Every clearance here is in the API, with alerts when new ones post.